



Preferred Drug List

NEW DRUG REVIEW

Proprietary Name: Besivance™

Common Name: Besifloxacin

PDL Category: Ophthalmic Quinolones

<u>Comparable Products</u>	<u>Preferred Drug List Status</u>
Ciprofloxacin	Preferred
Vigamox®	Preferred
Zymar®	Non-Preferred

Summary

Indications and Usage: Treatment of bacterial conjunctivitis.¹

Mechanism of Action: Fluoroquinolone antibacterial.¹

Dosage Forms: Ophthalmic Suspension: 0.6%

Recommended Dosage: Instill one drop in the affected eye(s) three times daily, four to twelve hours apart for 7 days.¹

Common Adverse Drug Reactions: Conjunctival redness.¹

Contraindications: None.¹

Manufacturer: Bausch & Lomb Inc.

Analysis: Besivance™ is a new ophthalmic fluoroquinolone indicated for the treatment of bacterial conjunctivitis. In the trials used to gain FDA approval, Besivance™ was compared only to its vehicle for the treatment of bacterial conjunctivitis. Ophthalmic fluoroquinolones are not considered first line therapy for the treatment of bacterial conjunctivitis from the American Academy of Ophthalmology guidelines. Preferred alternatives appear on the Preferred Drug List which are considered first line agents for the treatment of bacterial conjunctivitis, have similar clinical efficacy, and are more cost effective. Therefore, it is recommended that Besivance™ be added to the Preferred Drug List as a non-preferred drug.

IME Recommendation:

<input type="checkbox"/> Preferred Drug	<input type="checkbox"/> Recommended Drug
<input checked="" type="checkbox"/> Non-Preferred Drug	<input type="checkbox"/> Non-Recommended Drug
<input type="checkbox"/> Preferred Drug with Conditions	

1. Besivance™ [package insert]. Tampa, FL: Bausch & Lomb, Inc.; 2009.